Executive Management

Thomas Meier was appointed CEO of Santhera in October 2011 after having served seven years as Chief Scientific Officer for the Company. He was the founder and CEO of MyoContract, a Basel-based research company focused on orphan neuromuscular diseases, which he merged in 2004 with Graffinity to form today’s Santhera. Mr Meier holds a PhD in biology from the University of Basel. Read more...